Unanswered Ethics Questions of Physicians Against Drug Shortages Co-Chair Leads to Inquiry to Board’s Complaint Unit.
Brock-Utne’s article in a medical publication doesn’t disclose payments of $48,000+ from drug and medical device companies.
The group claims to have no conflicts of interest, no vested financial interest in the issue of drug shortages and no outside funding. But the financial ties to drug and medical device companies of Stanford Professor Emeritus Dr. Brock-Utne and other co-chairs call these claims into question.
A Senate Investigative Subcommittee and 60 Minutes report that Kaleo’s Evzio drug skyrocketed 600%, costing taxpayers millions. Yet that didn’t stop leaders of Physicians Against Drug Shortages (PADS) from promoting another of the pharmaceutical company’s drugs.
“It’s about money,” Declares Physicians Against Drug Shortages’s “Pro Bono” Executive Director Philip Zweig — But Whose Money?
If they had asked, they may have learned that Physicians Against Drug Shortages Executive Director Philip Zweig has been employed by and has direct financial ties to medical device manufacturing companies.
Doctors and others affiliated with Physicians Against Drug Shortages certainly have a right to present their point of view. But are media outlets doing enough to allow readers to evaluate the veracity of op-eds, guest columnists, media pundits and quoted “experts”?
Quotes by Physicians Against Drug Shortages spokespersons and op-ed bios by its members provide little in the way of details about the group. In a couple opinion pieces, PADS members describe themselves as executive director or co-chairs of a “pro bono patient advocacy group.”